Asset Details
Do you wish to reserve the book?
Mutant APC promotes tumor immune evasion via PD-L1 in colorectal cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Mutant APC promotes tumor immune evasion via PD-L1 in colorectal cancer
Do you wish to request the book?
Mutant APC promotes tumor immune evasion via PD-L1 in colorectal cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Mutant APC promotes tumor immune evasion via PD-L1 in colorectal cancer
2021
Overview
PD-L1 expression is elevated in various human cancers, including colorectal cancer. High levels of PD-L1 expressed on tumor epithelial cells are one of the potential mechanisms by which tumor cells become resistant to immune attack. However, PD-L1 regulation in tumor cells is not fully understood. Here we demonstrate that mutations in the adenomatous polyposis coli (
APC
) gene lead to colonic epithelial cell resistance to CD8
+
T cell cytotoxicity by induction of PD-L1 expression. Mechanistically, this occurs as a result of the β-catenin/TCF4 complex binding to the PD-L1 promoter, leading to increased transcription. Our findings not only reveal a novel mechanism by which
APC
mutations induce tumor immune evasion via an immune checkpoint pathway but also pave the way for developing β-catenin or TCF4 inhibitors as possible new options for immune checkpoint inhibition.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
/ 13/109
/ 13/2
/ 13/31
/ 13/51
/ 13/89
/ 38/22
/ 38/70
/ 38/77
/ 82/80
/ Adenomatous Polyposis Coli Protein - genetics
/ Adenomatous Polyposis Coli Protein - immunology
/ Animals
/ B7-H1 Antigen - biosynthesis
/ Cancer
/ CD8-Positive T-Lymphocytes - immunology
/ Colorectal Neoplasms - drug therapy
/ Colorectal Neoplasms - genetics
/ Colorectal Neoplasms - immunology
/ Humans
/ Immune checkpoint inhibitors
/ Medicine
/ Mice
/ Mutation
/ Oncology
/ Polyps
